Just like a mobile electronic device, every living cell contains a 'rechargeable battery' formed by pairs of inter convertible chemicals. The key chemicals within the cell are ATP and ADP, which are interconverted by the reactio n ATP ↔ ADP + phosphate. This reaction is maintained by catabolism many orders of magni tude away from equilibrium, yielding a high ratio of ATP to ADP that is used to drive energy-requiring processes. In animal cells, ATP is mainly generated by the mitochondrial ATP synthase, thus 'charging the batter y' . Almost every other function that cells perform requires energy, and most are driven by the hydrolysis of ATP back to ADP and phosphate, thus 'discharging the batter y' . Clearly, ATP generation needs to remain in balance with ATP consumption, and regulatory proteins that sense ATP and ADP levels would be a logical way to achieve this. However, all eukaryotic cells express high levels of adenylate kinase, and the reversible reaction it catalyses (2ADP ↔ ATP + AMP) is usually maintained close to equilibrium. This means that any rise in the ADP/ATP ratio, which signifies falling energy status, causes the adenylate kinase reaction to be displaced towards ATP and AMP production. Thus, falling cellular energy is associated with increases not only in ADP but also AMP. The relative increase in concentration is always much greater for AMP than ADP, although the absolute concentration of AMP remains lower than that of ADP unless energy stress becomes severe (FIG. 1) . Thus, it seems logical that proteins sensing cellular energy status should monitor either the ADP/ATP or AMP/ATP ratio, or both. A small number of metabolic enzymes do directly sense the AMP/ATP ratio, including the muscle isoforms of glycogen phosphorylase and phosphofructokinase (which are involved in glycogen breakdown and glyco lysis and are activated by an increasing AMP/ATP ratio) and fructose-1,6-bisphosphatase (which is involved in gluconeogenesis and is inhibited by an increasing AMP/ ATP ratio). However, the principal energy sensor in most eukaryotic cells seems to be AMP-activated protein kinase (AMPK)
are involved in glycogen breakdown and glyco lysis and are activated by an increasing AMP/ATP ratio) and fructose-1,6-bisphosphatase (which is involved in gluconeogenesis and is inhibited by an increasing AMP/ ATP ratio). However, the principal energy sensor in most eukaryotic cells seems to be AMP-activated protein kinase (AMPK) 1 . In support of this, increases in AMP/ ATP and ADP/ATP ratios during stresses such as muscle contraction 2 , ischaemia in cardiac muscle 3 or treatment of hepatocytes with metformin 4 are larger in cells or tissues in which AMPK, or its essential activating upstream kinase liver kinase B1 (LKB1; also known as STK11), have been knocked out.
In this Review article, we describe how AMPK monitors cellular energy status by sensing increases in the ratios of AMP/ATP and ADP/ATP, as well as other signals. Moreover, we examine how it regulates energy balance at the cellular level by activating catabolic pathways that generate ATP while conserving ATP by downregulating anabolic pathways. Finally, we discuss results showing that AMPK also regulates metabolism and energy balance at the whole-body level, especially via effects on the hypothalamus, as well as recent findings suggesting that AMPK conserves energy by regulating non-metabolic processes, such as the cell cycle and neuronal membrane excitability.
AMPK subunits and regulation
Genes encoding AMPK subunits are found in essentially all eukaryotes. AMPK and its orthologues seem to exist universally as heterotrimeric complexes comprising a catalytic α-subunit and regulatory β-and γ-subunits, the domain organizations of which are summarized in FIG. 2 .
The kinase activity of the αβγ-complexes, in animals from nematodes to humans, is instantaneously increased by AMP by as much as tenfold, although owing to technica l limitations with the assay 5 , the effect observed is usually smaller. It has been argued that this allosteric activation by AMP (which gave the kinase its name) may not be relevant under physiological conditions because of competition at the allosteric site by ADP and ATP 6 . However, as shown in FIG. 1b , an increase in the ADP/ATP ratio of only tenfold is sufficient for the cellular concentrations of the three adenine nucleotides to become equal. Although this would represent quite a severe stress and might only occur in pathological states (such as ischaemia) rather than under more physio logical conditions (such as exercise), the ADP/ATP ratio would still be still many orders of magnitude away from equilibrium and could still drive energy-requiring processes.
AMPK catalytic subunits contain a conventional Ser/ Thr kinase domain at the amino terminus. In all species, the activity of the complex increases more than 100-fold 5 when a conserved Thr residue in the activatio n loop (which is conventionally referred to as Thr172 owing to its position in the original rat sequence 7 ) is phosphorylated by upstream kinases. In mammals, the major upstream kinases are the LKB1-STRAD-MO25 complex [8] [9] [10] (which was originally identified genetically as a tumour suppressor) and the Ca 2+ /calmodulin-activated protein kinase kinases, especially CaMKKβ (also known as CaMKK2) [11] [12] [13] . The LKB1-STRAD-MO25 complex provides a high basal level of phosphorylation at Thr172 that is modulated by the binding of AMP to the AMPK γ-subunit, which promotes phosphorylation and inhibits dephosphorylation 14, 15 . Although allosteric activation is only caused by AMP, it has recently been found that the effects on phosphorylation and dephosphorylation can also be produced by ADP 16, 17 . The effects of AMP and ADP on phosphorylation require N-terminal myristylation of the β-subunit 17, 18 . Because AMP and ADP bind the γ-subunits of AMPK with similar affinity to ATP 16 (which does not cause activation) and ADP is usually present in cells at higher concentrations than AMP (FIG. 1b) , ADP may be the key activating signal that promotes net Thr172 phosphorylation during moderate energy stress. However, allosteric activation by AMP would further amplify activation during a more severe stress. This complex mechanism (FIG. 1) allows the system to provide a graded response of AMPK activity over a wide range of stress levels.
The alternative activating pathway, which involves CaMKKβ, triggers activation of AMPK in response to increases in cell Ca 2+ without necessarily requiring any change in AMP or ADP levels. In tumour cells that have lost the tumour suppressor LKB1 owing to somatic mutations, treatments that increase AMP and ADP levels do not normally activate AMPK 8 because basal CaMKKβ activity is too low for the effects of nucleotide binding on phosphorylation status to become evident. However, these treatments can cause AMPK activation in such cells if intracellular Ca 2+ is also increased 19 . This emphasizes that the effects of AMP and/or ADP on Thr172 phosphorylation status are a result of their binding to AMPK, and such effects are independent of the upstream kinases and phosphatases that phosphorylate or dephosphorylate Thr172.
AMPK structure
Although there is not yet a structure for a complete AMPK heterotrimer, the structures of various combinations of domains have been determined by X-ray crystallography. At the N terminus of the α-subunit is a conventional kinase domain immediately followed by an auto-inhibitor y domain (AID), so-called because constructs containing the kinase domain plus the AID are much less active than those containing the kinase domain alone 20, 21 . The AID is followed by an extended 'linker peptide' that connects the AID to the α-subunit carboxy-termina l domain (α-CTD). A recent structure 16 showed that this linker (coloured red in FIGS 2, 3) wraps around the γ-subunit as if holding it in a tight embrace. (FIG. 2) . AMPK is activated by increases in AMP and ADP as the cellular concentrations of ATP, ADP and AMP change. In the basal state (top left), sites 1 and 3 in the γ-subunit are occupied by ATP (site 4 is always occupied by AMP). Replacement of ATP by ADP (or AMP) at site 3 during moderate stress (top centre) promotes phosphorylation of Thr172 (bottom centre), causing a 100-fold increase in activity (indicated by two stars). Replacement of ATP by AMP at site 1 during more severe stress causes a further tenfold allosteric activation (indicated by a third star, bottom right). As cellular energy status returns to normal, AMP at site 1 and ADP or AMP at site 3 are progressively replaced by ATP (moving from right to left on the bottom row). This promotes the dephosphorylation of Thr172 and a return to the basal state. b | The graph shows changes in the predicted concentrations of ATP, ADP and AMP on going from an unstressed, fully charged cell (left) to a cell undergoing a severe energy stress (right), which corresponds to a tenfold increase in ADP/ATP ratio. The graph was generated by assuming that the adenylate kinase reaction was at equilibrium and that the total concentration of adenine nucleotides remained constant. Note that in a fully charged cell (left), AMP concentration is very low, but its percentage change in concentration as ADP/ATP increases is always much greater than those of ATP or ADP. CaMKKβ, Ca 2+ /calmodulin-activated protein kinase kinase-β; LKB1, liver kinase B1. 
Allosteric activation
The activation of an enzyme by non-covalent binding of a ligand (an allosteric activator) that binds at a site distinct from the catalytic site.
Activation loop
A sequence segment in the C-terminal lobe of protein kinases that often plays a key part in switching the kinase on; in many cases, the kinase is only active after phosphorylation of this loop.
LKB1-STRAD-MO25 complex
A heterotrimeric complex containing the tumour suppressor protein kinase LKB1 (liver kinase B1) and the accessory subunits STRAD (STE20-related kinase adapter protein) and MO25 (also known as calcium-binding protein 39). LKB1 was found to be the gene that is mutated in a form of inherited cancer susceptibility (Peutz-Jeghers syndrome) and is also lost owing to somatic mutation in many human cancers.
N-terminal myristylation
The covalent attachment of 14 carbon saturated fatty acid (myristic acid), usually to the N terminus of a protein following cleavage of the initiating Met.
CBS repeat
Sequence motif usually occurring as two tandem repeats that form a Bateman domain. They are named after cystathionine β-synthase, in which the Bateman domain binds S-adenosyl Met.
Bateman domain
A domain formed by two tandem CBS repeats that associate together with central clefts that bind small molecules, especially adenosine derivatives.
The β-subunits contain a carbohydrate-binding modul e (CBM) (although note that this is absent in the constructs used to generate the structure in FIG. 3) , which causes mammalian AMPK to associate with glyco gen particles 22, 23 . The functional significance of this remains uncertain, although it may serve to colocalize AMPK with downstream targets located in the glycogen particl e, such as glycogen synthase. The β-subunit C-terminal domain (β-CTD) interacts with both the α-CTD and the γ-subunit, thus forming the core of the complex. The γ-subunits contain four tandem repeats of a sequence motif termed a CBS repeat 24 (these are numbered as CBS1 to CBS4 in FIG. 2 and FIG. 3) . These tandem repeats occur in a small number of other proteins (including cystathionine β-synthase (CBS)), usually as just two repeats that assemble to form a Bateman domain
25
, with ligandbindin g sites in the cleft between the repeats 26 . Most Bateman domains bind adenosin e-containing ligands (usually ATP but in one case S-adenosyl Met 27 ), and mutations in them are associated with several human diseases, including a heart disease caused by mutations affecting the AMPK γ2-subunit 26, 27 . In AMPK, the four CBS repeats in the γ-subunits form a flattened disk with one repeat in each quadrant (seen from two different sides in FIG. 3) , and this disk contains four potential ligandbinding sites in the centre. These sites are numbered 1-4 according to the number of the repeat carrying a conserved aspartate residue involved in ligand binding 6 , and they have variable occupancies in the crystal structures of partial complexes from mammals and fungi 16, [28] [29] [30] . In the mammalia n γ1-subunit, site 2 appears to be always empty and site 4 to have a tightly bound AMP, whereas sites 1 and 3 represent the regulatory sites that bind AMP, ADP or ATP in competition. AMP binding to site 1 seems to cause allosteric activation, whereas binding of AMP or ADP to site 3 seems to modulate the phosphorylation state of Thr172 (REF. 16) . A model 16 that can explain how binding of AMP or ADP, but not ATP, protects Thr172 against dephosphorylation has been discusse d previously 31 . One long-standing puzzle has been the identity of the signals that activate AMPK orthologues in fungi and plants, which are not allosterically activated by AMP 32, 33 . Under conditions in which the Saccharomyces cerevisiae Snf1 complex is activated, such as during glucose starvation, there are large increases in AMP/ATP and ADP/ATP ratios 32 . The γ-subunits in fungi and plants contain four CBS repeats (as in mammals), and crystal structures of partial complexes from Schizosaccharomyces pombe have been solved with AMP, ADP and/or ATP bound at different sites 30, 34 . These observations support the idea that the activating signal is an adenine nucleotide in fungi (as in mammals), and it was recently reported that ADP inhibit s dephosphorylation and inactivation of the S. cerevisiae complex 35 , with AMP having a smaller effect 36 . AMP had already been shown to inhibit dephosphorylation of a plant Snf1-related kinase 1 (SnRK1) complex 37 . These results suggest that ADP and/or AMP may be the elusive signals that activate the fungal and plant enzymes but that they work only via effects on the phosphorylation state of the kinase and not via the additional allosteric mechanism.
Regulation of AMPK in intact cells
In mammalian cells, AMPK is activated by various types of metabolic stresses, drugs and xenobiotics through the mechanisms described above, which involve increases in cellular AMP, ADP or Ca
2+
. These can now be regarded as the classical or 'canonical' AMPK activation mechanisms. However, recent work suggests that other stimuli activate AMPK via mechanisms that do not involve changes in the levels of AMP, ADP and Ca
, which can therefore be termed 'non-canonical' mechanisms. These distinct types of mechanism are addressed below.
Canonical activation by metabolic stresses, drugs and xenobiotics. The canonical mechanisms of activation of mammalian AMPK, which involve increases in AMP and ADP (FIG. 1) , explain why AMPK is activated by stresses that inhibit the catabolic production of ATP, such as starvation for glucose 38 or oxygen 39 or addition of a metabolic poison 40 , as well as by stresses that increase ATP consumption, such as muscle contraction 41 . AMPK is also switched on by numerous drugs and xenobiotics, including antidiabetic drugs (such as metformin, phenformin and thiazolidinediones 42, 43 ), plant products reputed to have health-promoting properties (resveratrol from grapes and red wine 44 , epigallocatechin gallate from green tea, capsaicin from peppers 45 , curcumin from turmeric 46 and even garlic 47 ) and plant products used in traditional Chinese medicine (berberine 48 and hispidulin 49 ). Metformin, which is now prescribed to more than 100 million people with type 2 diabetes worldwide, was derived from the natura l product galegine extracted from Galega officinalis, a plant reputedly used to treat diabetes-like conditions in medieval Europe. Although metformin activates AMPK, this may not explain all of the therapeutic effects of the drug. In fact, AMPKα1-knockout mice that also carry a liverspecific deletion of AMPKα2 display a normal hypoglycaemic response to metformin, and the acute effects of metformin on glucose production in isolated hepatocytes are also preserved 4 . The effect of metformin on glucose production may be explained by metformin causing an increase in AMP that directly inhibits the gluconeogenic enzyme fructose-1,6-bisphosphatase. One caveat in the interpretation of these experiments is that the fall in ATP (and hence the increase in AMP) caused by metformin was larger in cells lacking AMPK than in wild-type cells 4 , which suggests that the inhibition of fructose-1,6-bisphosphatas e by AMP may be accentuated in the absence of AMPK. Thus, although not completely ruling out a role for AMPK in metformin action, these results do indicate that other targets, such as fructose-1,6-bisphosphatase, are also important.
It has been suggested that metformin activates AMPK in L6 skeletal muscle cells by inhibiting AMP deaminase (the enzyme that breaks down AMP), thus causing AMP to accumulate 50 . Although this is an interes ting proposal, the concentration of metformin used to inhibit AMP deaminase (10 mM) was very high. The same study also reported that the ability of metformin to activate AMPK was not reduced by small interfering RNA knockdown of adenylate kinase. However, only the 'cytosolic' adeny late kinase 1 (AK1) isoform was knocked down and not the mitochondrial isoform, AK2, which might be the more relevant isoform when studying effects of a mitochondrial inhibitor. Also, we now know that increased phosphorylation of AMPK can be triggered by an increase in ADP alone, obviating any requirement for adenylate kinase to generate AMP.
Intriguingly, some of the AMPK activators described above, including resveratrol and metformin, extend healthy lifespan in Caenorhabditis elegans, and genetic studies show that the AMPK orthologue is required for these effects, as well as for the life-extending effects of dietary restriction 51, 52 . In both C. elegans and mammalian cells, AMPK upregulates genes involved in oxidative metabolism and oxidative stress resistance by regulating transcription factors of the abnormal dauer formation 16 (DAF-16)/forkhead box O (FOXO) family 53, 54 . This might contribute to its effects on healthy lifespan.
An important question is how these drugs and xenobiotics all manage to activate AMPK, despite the fact that their structures are so varied. Most modulate AMPK in intact cells but not in cell-free assays, suggesting that they activate AMPK indirectly. Using a cell line that expresses an AMP-and ADP-insensitive AMPK mutant, it has been shown that many of them, including metformin and resveratrol, activate AMPK indirectly by increasing cellular AMP and ADP, usually by inhibiting mitochondrial ATP synthesis 55 . Many of these natural products appear to be defensive compounds produced by plants to deter infection by pathogens or grazing by insect or mammalian herbivores. Consistent with this, resveratrol is produced in grapes in response to fungal The right-hand view is rotated approximately 180° about the y axis compared to the left-hand view. The constructs crystallized contained only the carboxy-terminal domain of the β-subunit (β-CTD) and also lacked a flexible loop in the C-terminal domain of the α-subunit (α-CTD). The α-subunit auto-inhibitory domain (AID) was present but was not resolved in this crystal form; in the left-hand view, its approximate location would be just to the right of the junction between the α-subunit C-terminal lobe (C-lobe; green) and the α-linker (red). The crystals contained AMP bound at sites 3 and 4. Note how in this structure, access to the Thr172 site is restricted by the close association of the α-CTD with the kinase domain (left-hand view). In addition, note how AMP bound in site 3 is not visible because it is covered by the 'α-hook' structure of the linker peptide (right-hand view, linker peptide in red). N-lobe, N-terminal lobe of kinase domain; γ-NTD, N-terminal region of γ-subunit; γ-CBS1-CBS4, CBS repeats in γ-subunit. Data from REF. 16 .
Glutathionylation
The covalent attachment of glutathione to a protein via the formation of a mixed disulphide between the Cys moiety of glutathione and a Cys side chain of the protein.
Ataxia telangiectasia
An inherited human disorder of which the clinical signs include ataxia (uncoordinated movement) and telangiectasia (dilated blood vessels in the skin or mucous membranes). It is caused by mutation of the ataxia telangiectasia mutated (ATM) gene, which encodes a protein kinase of the phosphoinositide 3-kinase-like kinase (PIKK) family.
RAB-GAPs
Proteins carrying a RAB-GTPase activator protein function -that is, the ability to promote conversion of small G proteins of the RAB family from their active RAB-GTP state to their inactive RAB-GDP state. infection 56 , and G. officinalis is classed as a noxious weed in the United States because it is poisonous to herbivores. As the mitochondrial respiratory chain and ATP synthase contain several large multiprotein complexes, they might have many potential binding sites for hydrophobic xenobiotics that could inhibit their function. The production of mitochondrial poisons would be a useful general strategy for plants in order to deter pathogens or herbivores, with the side effect that plants would provide a rich source of AMPK activators. One could argue that by inhibiting mitochondrial ATP synthesis, these xenobiotics are acting in animals as mimetics of dietary restriction and/or exercise, both of which can decrease cellular energy status and have favourable effects on healthy lifespan.
Non-canonical activation by oxidative stress and genotoxic treatments. There are increasing indications that some types of cellular stress activate AMPK by noncanonical mechanisms that may not involve increases in AMP, ADP or Ca 2+ levels. In cultured cells, AMPK is activated by reactive oxygen species (ROS) such as hydrogen peroxide (H 2 O 2 ). At high ROS concentrations, AMPK activation may be secondary to the inhibitio n of mitochondrial ATP synthesis, with consequent rises in AMP and ADP levels 55 . However, it has been suggested that there is also a more direct mechanism involving oxidation or glutathionylation of two conserved Cys residues in the AMPK α-subunit 57 . It has also been suggested that H 2 O 2 can activate AMPK via a third mechanism involving a cytoplasmic form of the phosphoinositid e 3-kinase-like kinase (PIKK) ataxia telangiectasia mutated (ATM) 58 , which is the product of the gene mutated in human ataxia telangiectasia. Nuclear ATM is activated by double-strand breaks in DNA and is part of a key DNA damage-sensing pathway. However, it has recently become clear that there is also a cytoplasmic pool of ATM that has a role in the response to oxidative stress 59 . AMPK activation by low concentrations of H 2 O 2 is reduced in fibroblasts from patients with ataxia telangiectasia or from mouse embryo fibroblasts lacking ATM. ATM-dependent activation of AMPK by oxidative stress seems to require LKB1, as it is attenuated in cells lacking this upstream kinase 58 . Interestingly, ATM can phosphorylate LKB1, although it is not clear whether this has any effect on LKB1 activity 60 . Another class of factors that activate AMPK are geno toxic, DNA-damaging treatments such as etoposide 61 , doxorubicin 62 and ionizing radiation 63 , which activate AMPK initially in the nucleus 63 . There is evidence that these effects also require ATM but, surprisingly, they do not require LKB1 because the pathway is functional in LKB1-null cells 61, 63 . The detailed mechanism for this effect remains unclear. Finally, a recent genome-wide association study identified a strong association between single-nucleotide polymorphisms that mapped to the ATM gene on chromosome 11 and enhanced hypo glycaemic response to metformin treatment in humans 64 . Although the molecular explanation for this association remains unclear, it provides another tantalizin g link between metformin, ATM and AMPK.
To summarize this section, AMPK is activated in intact cells both by canonical pathways involving increases in AMP, ADP or Ca 2+ and by non-canonical pathways such as those triggered by ROS and DNAdamaging agents. Non-canonical pathways may involve the PIKK ATM, although the detailed mechanisms involved remain unclear.
Regulation of cellular energy metabolism AMPK and its orthologues phosphorylate downstream targets at Ser/Thr residues within a characteristic sequence motif, which has hydrophobic residues at the -5 and +4 positions and basic residues at -4 and -3, or both 65, 66 . Another basic residue at -6 is an additional positive determinant, and the best substrates (such as acetyl CoA carboxylase 1 (ACC1; also known as ACCα)) have additional hydrophobic residues forming an amphipathic helix N-terminal to the -5 position 67 . The principal effects of AMPK activation on cell metabolism are summarized in FIG. 4 . Consistent with a role in maintaining energy homeostasis, when AMPK is activated by energetic stress, it switches on catabolic pathways that generate ATP while switching off biosynthetic pathways that consume ATP.
Regulation of glucose uptake through glucose transporter type 4. Catabolic events mediated by AMPK include enhanced glucose uptake during muscle contraction, when the major metabolic fate of the glucose is catabolism to generate ATP. Muscle glucose uptake is also promoted by the hormone insulin, although this mainly occurs in resting muscle when the major metabolic fate of the glucose is glycogen synthesis, an anabolic process. In both cases, enhanced glucose uptake is mediated through translocation of glucose transporter type 4 (GLUT4; also known as SLC2A4) from intracellular storage vesicles to the plasma membrane. Fusion of these vesicles with the plasma membrane requires members of the RAB family of G proteins to be in their GTP-bound state 68 . Under basal conditions, RABs are held in an in active GDP-bound state by RAB-GAPs such as AKT substrate of 160 kDa (AS160; also known as TBC1 domain family member 4 (TBC1D4)) and TBC1D1, which are associated with the GLUT4 storage vesicles. The insulin-activated kinase AKT phosphorylates AS160 in muscle and adipocytes, triggering its association with 14-3-3 proteins and its consequent dissociation from the vesicles [69] [70] [71] . Similarly, AMPK phosphorylates TBC1D1 in contracting muscle, with similar effects 72, 73 . In either case, dissociation of these RAB-GAPs triggers the conversion of RABs to their active, GTP forms and the consequent fusion of the vesicles, carrying their GLUT4 cargo, with the plasma membrane. Consistent with this model, mice with a knock-in mutation (T649A) at a key AKT phosphorylation site in AS160 show impaired glucose disposal in vivo and impaired insulin-stimulated glucose uptake with isolated muscle 71 . It would be interesting to perform similar experiments with the AMPK site on TBC1D1 to confirm the mechanism by which AMPK regulates glucose uptake in contracting muscle. Whether AMPK, working via phosphorylation of TBC1D1 and perhaps other targets, entirely accounts for the acute effects of contraction on muscle glucose transport has been a matter of some controversy. In mouse knockouts of AMPKα2 (the major catalytic subunit isoform in muscle), the stimulatory effects of the AMPK activator 5-aminoimidazole-4-carboxamide riboside (AICAR) on glucose uptake were lost, but the effects of contraction were normal. In AMPKα1-knockout mice, both responses were normal 74 . By contrast, in mice with muscles lacking the upstream kinase LKB1 (in which activation of both AMPKα1 and AMPKα2 complexes by contraction was abolished), the effects of both AICAR and contraction on glucose uptake were lost 2 . One explanation for these discrepancies is that AMPKα1 may be able to compensate for AMPKα2 when the latter is absent. Recent results with muscle-specific AMPKβ1/ AMPKβ2 double knockout mice, which lack any detectable AMPK activity, have supported the idea that AMPK activation is crucial during muscle contraction. The running speed and endurance of these mice was dramatically reduced, and they exhibited blunted muscle glucose uptake in response to treadmill exercise and markedly impaired contraction-stimulated glucose uptake in isolated muscles 75 . These results are consistent with the idea that AMPK represents the primary signalling pathway responsible for contractioninduced glucose uptake, although TBC1D1 may not be the only downstream target that mediates this effect.
Regulation of other catabolic pathways. AMPK also promotes glucose uptake into cells expressing only GLUT1 (which includes most cells other than those in muscle, liver and adipose tissue) via a mechanism that involves activation of GLUT1 that is already located at the plasma membrane 76 . Moreover, AMPK promotes fatty acid uptake into cardiac myocytes via translocation of vesicle s containing the fatty acid transporter CD36 to the plasma membrane 77 . The direct targets for AMPK that mediate these effects remain unknown. After glucose and fatty acids have entered the cell, AMPK can promote the catabolism of glucose via glycolysis and of fatty acids by enhancing their uptake into mitochondria and their consequent breakdown by the β-oxidation pathway. Activation of glycolysis occurs via phosphorylation of 6-phosphofructo-2-kinase/ fructose-2,6-biphos phatase (PFKFB), which catalyses the generation (and breakdown) of fructose-2,6-bisphosphate, a key allosteri c activ ator of the glycolytic enzyme 6-phosphofructo-1-kinas e (PFK1). However, this only occurs in cells expressing the PFKFB2 isoform of PFKFB, such as cardiac myocytes 39 , or the PFKFB3 isoform, such as monocytes and macrophages 78 . Uptake of fatty acids into mitochondria, which seems to be the rate-limiting step in β-oxidation, is promoted by AMPK via phosphorylation and in activation of the ACC2 (also known as ACCβ) isoform of ACC. This results in a drop in concentration of the ACC product, malonyl CoA, an inhibitor of fatty acid entry into mitochondria mediated by the carnitine O-palmitoyltransferase 1 (CPT1) system 79 .
Regulation of mitochondrial biogenesis and mitophagy.
Another crucial process activated by AMPK is mitochondrial biogenesis (FIG. 4) , which in the longer term generates increased capacity for the oxidative cata bolism of both glucose and fatty acids. Repeated daily dosing of rats with AICAR results in increased expression of mitochondrial genes in muscle 80 , as well as increased exercise endurance 81 (the latter finding prompted the World Anti-Doping Agency to ban the use of AICAR in competitive sports). The AMPKβ1/AMPKβ2 double knockout mice mentioned above, which lack any AMPK activity in muscle, also had greatly reduced muscle mitochondrial content 75 . The 'master regulator' of mitochondrial biogenesis is peroxisome proliferator-activated receptor-γ co-activator 1α (PGC1α), a co-activator that enhances the activity of several transcription factors acting on nuclear-encoded mitochondrial genes 82 . AMPK directly phosphorylates PGC1α, which has been proposed to cause activation of its own transcription via a positive feedback loop 83 . An alternative mechanism by 
Mitophagy
The special form of autophagy by which mitochondria (probably in a damaged or defective state) are engulfed by autophagosomes and degraded, and their contents recycled for re-use.
Arcuate nucleus
An anatomical region of the hypothalamus at the base of the brain that appears to have a particular role in feeding and appetite.
Ghrelin
A 28-amino-acid peptide that is released by cells of the stomach and represents a 'hunger signal' .
Presynaptic neurons
Neurons acting immediately upstream of the neurons under study. Presynaptic neurons release neurotransmitters directly onto the neurons of interest.
Miniature excitatory postsynaptic currents
Small depolarizing currents that can be measured by patch clamping of a neuron. The currents are generated by packets of neurotransmitters released from a presynaptic neuron upstream of the patch-clamped neuron. These currents can be observed by applying tetrodotoxin to inhibit the firing of action potentials in the neuron.
Ryanodine receptors
Ca 2+ release channels in the sarcoplasmic/endoplasmic reticulum of muscle cells and neurons. These receptors are activated by Ca 2+ and blocked by the plant product ryanodine.
which AMPK has been proposed to activate PGC1α is through promotion of its deacetylation by increasing the concentration of NAD, which is the co-substrate for the deacetylase sirtuin 1 (SIRT1) 84 . As well as increasing mitochondrial biogenesis, AMPK is involved in the turnover of mitochondria via the special form of autophagy termed mitophagy (FIG. 4) . UNC-51-like kinase 1 (ULK1) and ULK2, the mammalian orthologues of the yeast Atg1 kinase that initiates the autophagy cascade, form stable complexes with AMPK 85 , and AMPK phosphorylates and activates ULK1, thus triggering autophagy 86, 87 . In cells in which endogenous ULK1 was replaced by a kinase-inactive mutant or by a mutant in which the AMPK phosphorylation sites were substituted by Ala, mitochondria displaying aberrant morphology and reduced membrane potential were observed following nutrient starvation 86 . This supports the idea that phosphorylation of ULK1 by AMPK is required for the clearance of dysfunctional mitochondria. Mitochondria are the main site of production of ROS in the cell and are particularly susceptible to oxidative damage. By recycling components of damaged mitochondria, mitophagy may be as important in maintaining a healthy cellular ATP-generating capacit y as the production of new mitochondria.
Regulation of anabolic pathways. Consistent with its role in cellular energy homeostasis, AMPK also conserves ATP by switching off almost all anabolic pathways, including the biosynthesis of lipids, carbohydrates, proteins and ribosomal RNA. It achieves this in part by phosphorylating and/or regulating enzymes or regulatory proteins that are directly involved in these pathways, including ACC1 (REF. 88 ) (involved in fatty acid synthesis), glycerol phosphate acyl-transferase 89 (involved in triglyceride and phospholipid synthesis), 3-hydroxy-3-methylglutaryl CoA reductase 90 (involved in cholesterol synthesis), glycogen synthase 91 (involved in glycogen synthesis), tuberous sclerosis 2 (TSC2; also known as tuberin) 92 and regulatoryassociated protein of mTOR (RAPTOR) 66 (regu lators of the target of rapamycin (TOR) kinase, which promotes protein synthesis) and transcription initiation factor IA (TIFIA; also known as RRN3) 93 (a transcription factor for RNA polymerase I, which is responsible for ribosomal RNA synthesis). In many cases, AMPK also downregulates expression of the proteins involved in these pathways, including ACC1 and other lipogenic enzymes (probably via phosphorylation of the lipogenic transcription factor sterol regulatory element-binding protein 1C (SREBP1C) 94 ) and the gluconeogenic enzymes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase (by phosphorylation of CREB-regulated transcription co-activator 2 (CRTC2; also known as TORC2) 95 and/or by phosphorylation and nuclear exclusion of the class IIa histone deacetylase family, which deacetylate and activate FOXO family transcription factors 96 ). With the exception of gluconeogenesis, most of these anabolic pathways are required for cell growth, and in many cases expression of the enzymes involved is upregulated in tumours. By downregulating these pathways, AMPK not only conserves ATP but also exerts a cytostatic, antitumour effect, which is consistent with the hypothesis that it exerts most, if not all, of the tumour suppressor effects of its upstream kinase, LKB1.
Regulation of whole-body energy metabolism
In mammals, AMPK can also influence metabolism and energy balance at the whole-body level, particularly through its actions in the hypothalamus of the brain.
AMPK and control of appetite. The primary appetite control centre is the arcuate nucleus of the hypothalamus, in which increased electrical activity in neuro peptide Y and agouti-related protein-expressing neurons (NPY/ AgRP neurons) induces feeding, whereas increased activit y in pro-opiomelanocortin-expressing neurons (POMC neurons) inhibits feeding 97 . Kinase assays in dissected hypothalamic regions from rodents show that hormones that inhibit feeding, such as the adipokine leptin, inhibit the α2 isoform of AMPK 98 , whereas those that promote it, such as the hormone ghrelin from the stomach, the adipokine adiponectin or cannabinoids, activate AMPK (the specific isoform was not determined) [98] [99] [100] [101] . Direct injection into the hypo thalamus of pharmacological activators of AMPK or of DNA encoding activated mutants also promotes feeding 98, 99 . Although leptin inhibits AMPKα2 in the hypothalamus 98 , mice in which AMPKα2 was specifically knocked out in NPY/AgRP neurons or POMC neuron s displayed only minor changes in food intake and still exhibited decreased food intake in response to leptin 102 . A possible explanation for this anomaly was provided by a recent report suggesting that it is in presynaptic neuro ns upstream of NPY/AgRP neurons, rather than in the NPY/AgRP or POMC neurons themselves, that regulation of AMPK is crucial 103 . The frequency of miniatur e excitatory postsynaptic currents in the NPY/ AgRP neurons was used as a measure of neuro transmitter release from presynaptic neurons acting upstream. Using various pharmacological agents, evidence was obtained for a model in which ghrelin, which is released from the stomach during fasting, activ ates AMPK in presynaptic neurons via growth hormone secretagogue receptor type 1 (GHSR) (FIG. 5a) . These receptors activate heterotrimeric G proteins containing G q (also known as G 11 ), which trigger intracellular Ca 2+ release and therefore lead to the activation of AMPK by the CaMKKβ pathway 104 . Consistent with this, CaMKKβ-deficient mice show reduced expression of NPY and AgRP -but not POMC -in the hypo thalamus and fail to increase their food intake in response to ghrelin 105 . Although the critical downstream target (or targets) for AMPK in the presynaptic neurons remains unclear, its activation seems to initiate a positive feedback loop in which Ca 2+ release via ryanodin e receptors causes sustained activation of AMPK and release of Ca 2+ and consequent neurotransmitter release onto the NPY/AgRP neurons. This in turn promotes sustained feeding, which owing to the positive feedback loop continues even after ghreli n stimulation has ceased. According to this model, feeding only stops when leptin released by adipocytes stimulates release from neighbouring POMC neurons 
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Ventromedial hypothalamus
An anatomical region of the hypothalamus at the base of the brain that appears to have a role in glucose sensing and activation of the sympathetic nervous system. of opioids, which act via μ-opioid receptors in the presynaptic neurons upstream of the NPY/AgRP neurons to inhibit AMPK (the mechanism for this latter effect remains unknown) (FIG. 5b) . An interesting parallel exists between this proposed neural circuit and the 'reset-set' or 'flip-flop' memory storage circuits used in electronic devices. These circuits are switched on by signals coming in via the 'set' input and remain switched on even in the absence of further stimulation until a signal is received on the 'reset' input. By analogy, hunger signals such as ghrelin represent the set inputs that switch on AgRP neurons and trigger feeding, and feeding would continue until the satiety signal, leptin, resets the circuit by acting on the POMC neuron. This model is consistent with observed diurnal patterns of plasma ghrelin and leptin in humans eating normal meals 106 . If excess food is available, there may be survival value in continuing to eat until the leptin signal coming from adipocytes indicates that fat stores have been replenished, rather than stopping eating as soon as the hunger signal from the stomach (ghrelin) has ceased. AMPK in glucose sensing and sympathetic nerve activity. AMPK in the neighbouring ventromedial hypothalamus also seems to have important roles in controlling whole-body energy balance. There is evidence that it is involved in the sensing of low blood glucose by promoting the release of counter-regulatory hormones (adrenaline and glucagon) that stimulate glucose production by the liver 107 . Thyroid hormones also inhibit AMPK in this region 108 , increasing the activity of sympathetic nerves, which increase energy expenditure by promoting fat oxidation in muscle or brown adipose tissue 108 . Interestingly, in whole-body mouse knockouts of AMPKα2, there is increased production of catecholamines 109 , which is consistent with the idea that inhibition of AMPK can promote activity of the sympatheti c nervous system. from intercellular stores via ryanodine receptors, creating a positive feedback loop that causes continued release of neurotransmitter onto the NPY/AgRP neuron, even when ghrelin stimulation ceases. The NPY/AgRP neurons promote feeding (and inhibit the POMC neurons, which inhibit feeding). b | Feeding continues (even in the absence of ghrelin) until the POMC neurons are stimulated by the 'satiety signal', leptin. Activity of these neurons inhibits feeding and also promotes release of opioids that inhibit AMPK in the presynaptic neurons upstream of the NPY/AgRP neurons, switching them back to an inactive state. GHSR, growth hormone secretagogue receptor type 1.
Circadian rhythms
Biological rhythms that follow the normal 24 hour cycle; although endogenously driven and thus continuing in the absence of external cues, they are often entrained or modified by external stimuli such as light or food availability.
Suprachiasmatic nucleus
A hypothalamic bilateral structure that is the central pacemaker of circadian rhythms in mammals.
Delayed rectifier potassium channels
A group of voltage-gated potassium channels that open and close slowly in response to membrane depolarization. By allowing potassium ions to flow out of cells down their concentration gradient and thus oppose subsequent depolarization, these channels regulate the frequency of action potentials.
AMPK and circadian rhythms. In most mammals, whole-body metabolism exhibits circadian rhythms, via which the timing of feeding and metabolism are synchronized with the daily cycle of light and darkness. The suprachiasmatic nucleus of the hypothalamus is the site of the 'master clock' that generates these rhythms. However, the proteins involved in establishing these rhythms are also expressed at peripheral sites such as the liver, forming 'slave clocks' that can oscillate independently under certain circumstances 110 . These proteins include the transcription factors brain and muscle ARNT-like 1 (BMAL1; also known as ARNTL) and CLOCK, which form a hetero dimer that activates the expression of many genes, two of which are the PER (period) and CRY (cryptochrome) genes. Once synthesized, PER and CRY proteins bind to each other, become phosphorylated and then enter the nucleus, where they inhibit the BMAL1-CLOCK complex. This delayed negative feedback loop results in the rhythmic expression not only of PER and CRY themselves but also of numerous other genes driven by BMAL1-CLOCK. AMPK has been found to phosphorylat e CRY1, reducing its association with PER2 and instead increasing its binding to F-box and Leu-rich repeat protein 3 (FBXL3), a ubiquitin ligase that promotes CRY1 ubiquitylation and degradation 111 . This would have the effect of extending the period of the endogenous rhythm. In mouse embryo fibroblasts synchronized by serum starvation, treatment with low glucose or the AMPK activator AICAR reduced the amplitude and increased the period of the circadian rhythm of a luciferase reporter gene driven by the BMAL1-CLOCK promoter; these effects were lost in cells lacking LKB1 or AMPK. It has been known for many years that the phosphorylation of AMPK targets such as ACC follows a circadian rhythm in rodent liver that is linked to the times of feeding 88 . The more recent results 111 suggest that AMPK may have a crucial role in determining these circadian rhythms.
AMPK functions beyond metabolism
Although AMPK is best known for its effects on metabolism, it has recently become clear that it may regulate energy levels by mediating effects that are not directly related to metabolism. Two of these are regulation of the cell cycle and modulation of membrane excitability.
Regulation of the cell cycle. Both DNA replication (in S phase) and mitosis (in M phase) are energy-requiring processes, and it would make little sense for cells that are deficient in energy to execute them. Consistent with this, activation of AMPK in cycling cells causes arrest in G1 phase before DNA replication 112 . This arrest is associated with phosphorylation of p53 at Ser15 (although it is not clear that this is a direct target for AMPK) and upregulation of expression of cyclin-dependent kinase inhibitor 1A (CDKN1A; also known as p21 WAF1 ), which is a product of a p53-activated gene 112, 113 . AMPK has also been reported to phosphorylate the C-terminal residue of CDKN1B (also known as p27 KIP1 ), causing its stabilization 114 . These effects may explain, at least in part, the ability of AMPK to cause cell cycle arrest.
Surprisingly, other studies suggest that AMPK activity is required for the completion of mitosis. An elegant chemical genetic screen, which involved expression of AMPKα2 with a mutation in the catalytic site that allowed it to utilize a chemically modified ATP, identified several novel targets for AMPK, all of which conformed with the established AMPK recognition motif 65, 66 . Many of these novel targets had roles in mitosis and cytokinesis and included components of the anaphase promoting complex (APC1 and CDC27), three of the regulatory subunits (PPP1R12A, PPP1R12B and PPP1R12C) that target protein phosphatase 1 to dephosphorylate myosin regulatory light chain (MRLC) at Ser19, and the protein kinase PAK2, which phosphorylates MRLC at Ser19 (REF. 115 ). The phosphorylation of AMPK at Thr172 and the phosphorylation of PPP1R12C at Ser452 by AMPK were elevated in mitotic cells, and stable expression of a S452A mutant PPP1R12C led to an increase in the proportion of multinucleated cells, indicating a defect in mitosis or cytokinesis. Relevant to this are findings that AMPK phosphorylated at Thr172 is specifically localized at several places within the mitotic apparatus in mitotic cells 116 . Intriguingly, Drosophila melanogaster embryos carrying AMPK-null mutations also display a high frequency of multinucleate or polyploid cells, and this could be rescued by expressing MRLC with phosphomimetic mutations at the sites equivalent to Thr18 and Ser19 in human MRLC 117 . It is not immediately apparent why a kinase activated by energy stress should be required for passage through mitosis. Perhaps mitosis is accelerated by AMPK in cells undergoing stress so that an orderly cell cycle arrest can occur in the ensuing G1 phase. However, it may be that this is an ancillary function of AMPK that is unrelated to its role as an energy sensor.
Regulation of membrane excitability. Remarkably, ATP turnover in the grey matter of brain is comparable with that in leg muscle during marathon running, explaining why an organ contributing only 2% of body weight can account for >20% of resting metabolism 118 . It has been estimated that the firing of action potentials accounts for 25-50% of this energy consumption, with synaptic transmission (which is triggered by action potentials) contributing most of the remainder 118, 119 . A mechanism that downregulated the firing of neuronal action potentials would therefore conserve a considerable amount of energy. Recent studies with HEK293 cells stably expressing the potassium channel Kv2.1 showed that AMPK activation activates these potassium channels by causing a shift in voltage gating to more negative membrane potentials. Identical effects were observed when activated AMPK (thiophosphorylated at Thr172 to make it resistant to phosphatases), but not an inactive mutant, was introduced into the cells via patch pipette 120 . AMPK phosphorylates purified Kv2.1 at two sites in its cytoplasmic C-terminal tail, and the effect of AMPK activation on voltage gating was lost in cells in which one of these (Ser440) was substituted with a non-phosphorylatable Ala 120 . Kv2.1 accounts for a large proportion of the delayed rectifier potassium channels in central neurons, and their activation has been proposed to reduce the firin g of action potentials down the axon 121 . Interestingly, introduction of active thiophosphorylated AMPK, but not an inactive mutant, into cultured rat hippo campal neurons via patch pipette caused a progressive decrease in the frequency of action potentials induced by a current pulse 120 . These results support the idea that AMPK activation may exert a neuroprotective role by limiting the rate of firing of action potentials, thus conserving energy when the energy status of neuronal tissue is compromised.
Conclusions and outstanding questions
There are now around one thousand papers on AMPK and its orthologues published every year, and in this Review we have only been able to cover a small number that we found particularly interesting. The classical pathways through which AMPK is activated by increases in AMP/ATP or ADP/ATP ratios or by increases in Ca 2+ are now becoming well understood, although our understanding of the protein phosphatases that dephos phorylate Thr172 remains incomplete. The 'non-canonical' mechanisms by which oxidative stress and genotoxic agents activate AMPK are another area that needs further investigation. Although AMPK is perhaps best known for regulating metabolism at the cellular level, in mammals it also regulates metabolism and helps to maintain energy balance at the whole-body level. It does this by mediating effects of hormones and other agents acting on neurons in different hypo thalamic regions, which regulate intake of food (and hence energy) and energy expenditure. AMPK also regulates diurnal rhythms of feeding and metabolism. By switching off biosynthetic pathways required for cell growth, AMPK activation exerts a cytostatic effect, helping to explain why its upstream activator, LKB1, is a tumour suppressor. Commensurate with its role in preserving cellular energy homeostasis, AMPK also downregulates ATP-requiring processes outside metabolism, including progress through the cell cycle (another potential tumour suppressor effect) and firing of action potentials in neuron s. Although it might be said that the AMPK field is approaching maturity, it seems certain that many exciting findings about the pathway remain to be discovered, and these insights might lead to novel drugs and other means of exploiting this knowledge.
